Ocular Therapeutix
Biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye.
Market cap
$1.5b
Enterprise value
$1.2b
Share price
$9.28 OCUL
loading funding rounds…
Baxter International(exited)
Versant Ventures(exited)
Polaris Partners(exited)
SV Health Investors(exited)
Ascension Ventures(exited)
Ascension(exited)
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 150 % | 18 % | 13 % | 9 % | (14 %) | 21 % | 81 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (179 %) | (151 %) | (129 %) | (232 %) | (459 %) | (379 %) | (158 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (15 %) | (138 %) | (138 %) | (304 %) | (439 %) | (377 %) | (164 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 115 % | 104 % | 104 % | 200 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.